Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Kun Pang, Zhenduo Shi, Liuya Wei, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100907-100907
Closed Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Xianjing Chu, Wentao Tian, Ziqi Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 92
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes
Huai Liu, Ling Tang, Yanxian Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 35
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 21
Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis
Zaigang Zhou, Xin Jiang, Yi Lei, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 20
Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation
Xiaoyan Xu, Tingxue Xie, Mengxin Zhou, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 17
Basic helix–loop–helix ARNT like 1 regulates the function of immune cells and participates in the development of immune-related diseases
Fanglin Shao, Zhipeng Wang, Luxia Ye, et al.
Burns & Trauma (2025) Vol. 13
Open Access | Times Cited: 4
Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review
Xinyan Wu, Zhigang Zhou, Qiang Cao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 38
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Zaigang Zhou, Haoxiang Wang, Jie Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127911-127911
Closed Access | Times Cited: 28
The role of circular RNAs in regulating resistance to cancer immunotherapy: mechanisms and implications
Yu Ma, Ting Wang, Xudong Zhang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 15
NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1
Zhiheng Zhang, Bojiao Song, Haowei Wei, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101040-101040
Closed Access | Times Cited: 13
Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME)
Mahvash Sadeghi, Sajad Dehnavi, Moosa Sharifat, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27480-e27480
Open Access | Times Cited: 12
The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment
Mengdan Xu, Shenglong Li
Cancer Letters (2024) Vol. 593, pp. 216969-216969
Closed Access | Times Cited: 12
Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors
Chengliang Sun, Yuling He, Gefei Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 3590-3605
Closed Access | Times Cited: 11
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application
Rui Zheng, Xiaobin Liu, Yufu Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance
Zhijie Xu, Zhou Hai-yan, Tongfei Li, et al.
Drug Resistance Updates (2024) Vol. 75, pp. 101098-101098
Closed Access | Times Cited: 10
HER2+ advanced gastric cancer: Current state and opportunities (Review)
Hui-Hui Hu, Saiqi Wang, Huichen Zhao, et al.
International Journal of Oncology (2024) Vol. 64, Iss. 4
Open Access | Times Cited: 9
The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways
Dengxiong Li, Fanglin Shao, Qingxin Yu, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Histone lactylation regulates PRKN-Mediated mitophagy to promote M2 Macrophage polarization in bladder cancer
Xiaolin Deng, Yuan Huang, Jinge Zhang, et al.
International Immunopharmacology (2025) Vol. 148, pp. 114119-114119
Closed Access | Times Cited: 1
Harnessing phytochemicals: innovative strategies to enhance cancer immunotherapy
Qianru Zhu, Ruonan Zhang, Min Jin Ha, et al.
Drug Resistance Updates (2025) Vol. 79, pp. 101206-101206
Open Access | Times Cited: 1
Resetting the Hsc70-mediated lysosomal degradation of PD-L1 via a supramolecular meso peptide for the restoration of acquired anti-tumor T cell immunity
Yujia Zhao, Dan Liu, Wenguang Yang, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
Rui Liu, Zhi Ji, Xia Wang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access | Times Cited: 1
CK2B Induces CD8+ T‐Cell Exhaustion through HDAC8‐Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti‐PD‐1 Therapy in Non‐Small‐Cell Lung Cancer
Shaochuan Liu, Shiya Ma, Gen Liu, et al.
Advanced Science (2025)
Open Access | Times Cited: 1
The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity
Hao Wu, J.F. Liu, Xinghua Zhang, et al.
Drug Resistance Updates (2025) Vol. 80, pp. 101222-101222
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top